Non hodgkin lymphoma therapeutics market research report 2020 radiant insights, inc

Non-Hodgkin Lymphoma Therapeutics Market Research Report 2020: Radiant Insights, Inc Summary GBI Research, the leading business intelligence provider, has released its latest research, 'Non-Hodgkin Lymphoma Therapeutics in Asia-Pacific Markets to 2020 - Novel Technologies Show Considerable Promise in Relapsed/Refractory Setting', which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Non-Hodgkin Lymphoma (NHL).

Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting The market in the APAC region was worth an estimated $1.1 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.6% to $1.7 billion in 2020. The expected launches of promising drugs, including novel protein kinase inhibitors and next-generation monoclonal antibodies, as well as the continued use of the current blockbuster, Rituxan/Mabthera, will be the key growth drivers.

The launch of premium-priced novel glycol-engineered antibody; obinutuzumab; kinase inhibitors including idelalisib and ibrutinib; and the mTOR inhibitor everolimus are also expected to have a significant impact, as is the anticipated approval of immunomodulatory agent Revlimid as a maintenance setting. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC NHL market.

Scope The report analyzes treatment usage patterns, market characterization, the pipeline, and key licensing and co-development deals in the four APAC markets of Australia, China, India and Japan. It includes - A brief introduction to NHL, including the disease's pathogenesis, etiology, diagnosis and treatment algorithms - In-depth analysis of currently marketed drugs for NHL, examining their safety, efficacy, treatment patterns and strengths/weaknesses and including a heat map that compares the drugs in terms of safety and efficacy - A comprehensive review of the pipeline for NHL, including individual analysis of a number of latestage pipeline drugs that are likely to enter the market during the forecast period; the pipeline is analyzed on the basis of Phase distribution, molecule type, program type, mechanism of action and molecular target

- Additional in-depth analysis of pipeline drug clinical trials by Phase, trial size, trial duration and program failure rate for each molecule type - Multi-scenario forecast data of the market to 2020, taking into account how the market may be affected by the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets - Discussion of the drivers of and barriers to market growth - In-depth analysis of all licensing and co-development deals that have occurred in the NHL market since 2006 Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting Reasons to buy The report will enhance your decision-making capability by allowing you to - Understand the NHL pipeline and the factors that indicate that it is becoming more innovative - Examine detailed profiles of promising pipeline products and gain an insight into how they are likely to compete in the market and who their main competitors will be - Follow the trends in NHL clinical trial size and duration in relation to industry averages and assess the potential risk of future developmental programs according to mechanism of action by considering the recorded clinical trial failure rates - Observe the potential growth patterns expected for the NHL market over the forecast period, identify which countries are expected to make the biggest contribution to this growth, and devise a more effective country - strategy through an understanding of key drivers and barriers in the NHL market - Accelerate and strengthen your market position by identifying key companies for strategic partnerships Table of Contents Table of Contents 6 1.1 List of Tables 8 1.2 List of Figures 8 2 Introduction 10 2.1 Symptoms 10 2.2 Etiology 11

2.3 Pathophysiology 11 2.4 Diagnosis 12 2.4.1 Biopsy 12 2.4.2 Laboratory molecular tests 12 2.4.3 Imaging tests 13 2.5 Classification 13 2.5.1 B-Cell lymphomas 14 2.5.2 T-Cell Lymphomas 16 2.6 Epidemiology 17 Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting 2.7 Prognosis and Disease Staging 18 2.7.1 Staging 19 2.8 Treatment Options 20 2.8.1 Surgery and Radiation Therapy 20 2.8.2 Stem Cell Transplantation 20 2.8.3 Pharmacological 20 2.8.4 Treatment Algorithms and Prescribing Habits 22 3 Marketed Products 24 3.1 Therapeutic Landscape 24 3.1.1 Immunotherapies 24 3.1.2 Targeted Therapies 29 3.1.3 Chemo-Regimens 32 3.2 Comparative Efficacy and Safety (Marketed Products) 34 4 Pipeline Products 37 4.1 Overall Pipeline 37

4.2 Pipeline Analysis by Molecule Type 38 4.3 Pipeline Analysis by Mechanism of Action 39 4.4 Clinical Trials 41 4.4.1 Failure Rate 41 4.4.2 Patient Enrollment and Clinical Trial Size 42 4.4.3 Duration 43 4.5 Promising Drug Candidates in the Pipeline 44 4.5.1 Idelalisib (GS-1101) - Gilead Sciences 44 4.5.2 Imbruvica (Ibrutinib) - Pharmacyclics/Janssen Biotech 45 4.5.3 Gazyva (Obinutuzumab) - Roche 45 Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting 4.5.4 Revlimid (lenalidomide) - Celgene 46 4.5.5 Afinitor (everolimus) - Novartis 47 4.6 Heat Map of Safety and Efficacy and Product Competitiveness Framework for Non-Hodgkin Lymphoma Pipeline 48 5 Market Forecast to 2020 51 5.1 Geographical Markets 51 5.1.1 APAC Market 51 5.1.2 India 52 5.1.3 Australia 55 5.1.4 China 58 5.1.5 Japan 60 5.2 Drivers and Barriers for the Disease Market 63 5.2.1 Drivers 63 5.2.2 Barriers 64

6 Deals and Strategic Consolidations 65 6.1 Major Co-development Deals 67 6.1.1 Roche Signs an Agreement with GlycArt and Genentech 68 6.1.2 Cell Therapeutics Enters Agreement with Bayer 68 6.1.3 Chugai Enters Co-development Agreement with Nippon Shinyaku for GA101 68 6.1.4 GlaxoSmithKline Enters Co-development Agreement with Genmab 69 6.1.5 Biogen Idec Enters Co-development Agreement with Genentech 69 6.1.6 Seattle Genetics Enters Co-development Agreement with Millennium 69 6.2 Major Licensing Deals 69 Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting 6.2.1 Spectrum Enters Licensing Agreement with Bayer for Zevalin 70 6.2.2 Janssen Biotech Enters Licensing Agreement with Pharmacyclics for PCI-32765 70 6.2.3 Lundbeck Enters Licensing Agreement with Cephalon 71 6.2.4 TG Therapeutics Enters Licensing Agreement with Ildong for Ublituximab 71 6.2.5 Provenance Enters Licensing Agreement with Merck Serono 71 6.2.6 Cephalon Enters Licensing Agreement with SymBio 71 6.2.7 Genentech Enters Licensing Agreement with Seattle Genetics 71 7 Appendix 72 7.1 Market Definitions 72 7.2 Abbreviations 72 7.3 Bibliography 75 7.4 Pipeline Tables 78 7.4.1 Discovery 78 7.4.2 Preclinical 79 7.4.3 Investigational New Drug-Filed 81

7.4.4 Phase I 82 7.4.5 Phase II 85 7.4.6 Phase III 89 7.5 Market Forecasts to 2020 90 7.5.1 Asia-Pacific 90 7.5.2 India 90 7.5.3 Australia 91 7.5.4 China 91 7.5.5 Japan 92 7.6 Research Methodology 92 7.6.1 Coverage 92 Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting 7.6.2 Secondary Research 93 7.6.3 Primary Research 93 7.6.4 Therapeutic Landscape 93 7.6.5 Geographical Landscape 95 7.6.6 Pipeline Analysis 96 7.7 Expert Panel Validation 96 7.8 Contact Us 96 7.9 Disclaimer 96 List of Tables Table 1: Non-Hodgkin Lymphoma Therapeutics, Most Common Chromosomal Aberrations Associated With NHL 12 Table 2: Non-Hodgkin Lymphoma Therapeutics, IWF Classification of Lymphoproliferative Diseases 14 Table 3: Non-Hodgkin Lymphoma Market, Classification of Non-Hodgkin Lymphoma 17

Table 4: Non-Hodgkin Lymphoma Market, IPI Good and Poor Prognostic Factors 18 Table 5: Non-Hodgkin Lymphoma Market, Ann Arbor Staging System for Lymphoma 19 Table 6: Non-Hodgkin Lymphoma Market, Commonly Used Chemo-Regimens 21 Table 7: Non-Hodgkin Lymphoma Market, Common Symptoms of Non-Hodgkin Lymphoma 26 Table 8: Non-Hodgkin Lymphoma Market, Endpoints of Various Chemotherapeutic Regimens (%) 33 Table 9: Non-Hodgkin Lymphoma Market, Efficacy Comparison of R-CHOP vs. CHOP 34 Table 10: Non-Hodgkin Lymphoma Market, Efficacy Comparison of CVP vs R-CVP 34 Table 11: Non-Hodgkin Lymphoma Market, Global, Average Clinical Trial Duration (Months) 43 Table 12: Non-Hodgkin Lymphoma Market, Global, Deals and Strategic Consolidations, 2006-2014 65 Table 13: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Discovery), 2014 78 Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting Table 14: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Preclinical), 2014 79 Table 15: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (IND-filed), 2014 81 Table 16: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Phase I), 2014 82 Table 17: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Phase II), 2014 85 Table 18: Non-Hodgkin Lymphoma Market, Global, Pharmaceutical Pipeline (Phase III), 2014 89 Table 19: Non-Hodgkin Lymphoma Market, Asia-Pacific, Market Forecast, 2013-2020 90 Table 20: Non-Hodgkin Lymphoma Market, India, Market Forecast, 2013-2020 90 Table 21: Non-Hodgkin Lymphoma Market, Australia, Market Forecast, 2013-2020 91 Table 22: Non-Hodgkin Lymphoma Market, China, Market Forecast, 2013-2020 91 Table 23: Non-Hodgkin Lymphoma Market, Japan, Market Forecast, 2013-2020 9 List of Figures Figure 1: Non-Hodgkin Lymphoma Market, Asia-Pacific, Distribution of Prevalence Population, 20132020 18

Figure 2: Non-Hodgkin Lymphoma Market, Treatment Algorithm for Indolent Non-Hodgkin Lymphoma, 2014 22 Figure 3: Non-Hodgkin Lymphoma Market, Treatment Algorithm for Aggresive Non-Hodgkin Lymphoma, 2014 23 Figure 4: Non-Hodgkin Lymphoma Market, Global, Rituxan, Annual Sales ($bn), 2006-2013 25 Figure 5: Non-Hodgkin Lymphoma Market, Global, Adcetris, Annual Sales ($m), 2011-2013 27 Figure 6: Non-Hodgkin Lymphoma Market, Global, Velcade, Annual Sales ($bn), 2007-2013 30 Figure 7: Non-Hodgkin Lymphoma Market, Global, Istodax, Annual Sales ($m), 2010-2013 31 Figure 8: Non-Hodgkin Lymphoma Market, Global, Comparative Safety and Efficacy of Marketed Products (Heat Map), 2014 36 Figure 9: Non-Hodgkin Lymphoma Market, Global, Pipeline by Stage of Development, Program Type and Route of Administration, 2014 38 Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting Figure 10: Non-Hodgkin Lymphoma Market, Global, Pipeline by Molecule Type and Stage of Development, 2014 39 Figure 11: Non-Hodgkin Lymphoma Market, Global, Pipeline by Mechanism of Action, 2014 40 Figure 12: Non-Hodgkin Lymphoma, Global, Pipeline by Mechanism of Action, Molecule Type and Stage of Development (Number), 2014 41 Figure 13: Non-Hodgkin Lymphoma Market, Global, Clinical Trial Failure Rate (%), 2014 42 Figure 14: Non-Hodgkin Lymphoma Market, Global, Clinical Trial Size (Participants), 2014 43 Figure 15: Non-Hodgkin Lymphoma Market, Global, Pipeline Clinical Trial Duration (Months), 2014 44 Figure 16: Non-Hodgkin Lymphoma Market, Global, Comparative Safety and Efficacy of Pipeline Products (Heat Map), 2014 50 Figure 17: Non-Hodgkin Lymphoma Market, Asia-Pacific, Market Size, 2013-2020 52 Figure 18: Non-Hodgkin Lymphoma Market, India, Treatment Usage Pattern ('000), 2013-2020 53 Figure 19: Non-Hodgkin Lymphoma Market, India, Annual Cost of Therapy ($), 2013-2020 54 Figure 20: Non-Hodgkin Lymphoma Market, India, Market Size ($m), 2013-2020 55

Figure 21: Non-Hodgkin Lymphoma Market, Australia, Treatment Usage Pattern ('000), 2013-2020 56 Figure 22: Non-Hodgkin Lymphoma Market, Australia, Annual Cost of Therapy ($'000), 2013-2020 57 Figure 23: Non-Hodgkin Lymphoma Market, Australia, Market Size ($m), 2013-2020 58 Figure 24: Non-Hodgkin Lymphoma Market, China, Treatment Usage Pattern ('000), 2013-2020 59 Figure 25: Non-Hodgkin Lymphoma Market, China, Annual Cost of Therapy, 2013-2020 59 Figure 26: Non-Hodgkin Lymphoma Market, China, Market Size ($m), 2013-2020 60 Read Complete Report with TOC @ http://www.radiantinsights.com/research/non-hodgkinlymphoma-therapeutics-in-asia-pacific-markets-to-2020-novel-technologies-show-considerablepromise-in-relapsed-refractory-setting Figure 27: Non-Hodgkin Lymphoma Market, Japan, Treatment Usage Pattern ('000), 2013-2020 61 Figure 28: Non-Hodgkin Lymphoma Market, Japan, Annual Cost of Therapy ($'000), 2013-2020 62 Figure 29: Non-Hodgkin Lymphoma Market, Japan, Market Size ($m), 2013-2020 63 Figure 30: Non-Hodgkin Lymphoma Market, Global Deals by Value, Year and Stage of Development, 2006-2014 66 Figure 31: Non-Hodgkin Lymphoma Market, Global, Deals by Phase, Molecule Type and Mechanism of Action, 2006-2014 67 Figure 32: Non-Hodgkin Lymphoma Market, Global, Co-development Deals by Geography, 2006-2014 68 Figure 33: Non-Hodgkin Lymphoma Market, Global, Licensing Deals by Geography, 2006-2014 70 Figure 34: GBI Research Market Forecasting Model 95 About Radiant Insights Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information, Visit Radiant Insights Contact: Michelle Thoras

Corporate Sales Specialist, USA Radiant Insights, Inc Phone: 1-415-349-0054 Toll Free: 1-888-202-9519 Email: sales@radiantinsights.com Blog URL: http://chemicalmaterialsmarket.blogspot.in/